Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. (Q42831059)
Jump to navigation
Jump to search
scientific article published on December 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes. |
scientific article published on December 2010 |
Statements
Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes (English)
T Forst
B Uhlig-Laske
U Graefe-Mody
C Friedrich
K Herbach
H-J Woerle
1 December 2010